Shawn E. Lupold, Ph.D. - Publications

2001 Johns Hopkins University, Baltimore, MD 
Pharmacology, Molecular Biology, Biochemistry

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA. Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis. Clinical Chemistry. PMID 30518666 DOI: 10.1373/clinchem.2018.293365  0.48
2018 Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE. Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer. Scientific Reports. 8: 7189. PMID 29739972 DOI: 10.1038/s41598-018-25320-z  0.48
2017 Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens. Bmc Cancer. 17: 32. PMID 28061773 DOI: 10.1186/s12885-016-3008-4  0.48
2016 Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE. Development and application of a novel model system to study 'active' and 'passive' tumor targeting. Molecular Cancer Therapeutics. PMID 27486224 DOI: 10.1158/1535-7163.MCT-16-0051  0.48
2015 Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA. Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. The Prostate. PMID 26499105 DOI: 10.1002/pros.23115  0.48
2015 Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWEese TL, Lupold SE. Systemic administration and targeted radiosensitization via chemically synthetic aptamer-siRNA chimeras in human tumor xenografts. Molecular Cancer Therapeutics. PMID 26438155 DOI: 10.1158/1535-7163.MCT-15-0291-T  0.48
2015 Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE. A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation. Nucleic Acids Research. 43: 4075-86. PMID 25845598 DOI: 10.1093/nar/gkv273  0.48
2015 Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R. Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 771-80. PMID 25501577 DOI: 10.1158/1078-0432.CCR-14-0891  0.48
2014 Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE. Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy. The Prostate. 74: 1655-62. PMID 25252191 DOI: 10.1002/pros.22883  0.48
2014 Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE. A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector. The Prostate. 74: 1286-96. PMID 25065656 DOI: 10.1002/pros.22845  0.48
2014 Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG. Evaluation of prostate-specific membrane antigen as an imaging reporter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 55: 805-11. PMID 24700883 DOI: 10.2967/jnumed.113.134031  0.48
2014 Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH. Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. Journal of Cellular Biochemistry. 115: 1505-15. PMID 24604720 DOI: 10.1002/jcb.24805  0.48
2014 Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE. Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen. Chemmedchem. 9: 1356-60. PMID 24591351 DOI: 10.1002/cmdc.201300549  0.48
2014 Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE. Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor. Nanomedicine (London, England). 9: 2729-43. PMID 24547783 DOI: 10.2217/nnm.13.207  0.48
2013 Johnson TJ, Höti N, Liu C, Chowdhury WH, Li Y, Zhang Y, Lupold SE, Deweese T, Rodriguez R. Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer. Cancer Gene Therapy. 20: 394-402. PMID 23764901 DOI: 10.1038/cgt.2013.34  0.48
2013 Ribas J, Lupold SE. The role of miR-21, an androgen-regulated MicroRNA, in prostate cancer Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications. 2147483647: 285-305. DOI: 10.1007/978-1-4614-6182-1_18  0.48
2012 Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R. Mechanism of growth inhibition of prostate cancer xenografts by valproic acid. Journal of Biomedicine & Biotechnology. 2012: 180363. PMID 23093837 DOI: 10.1155/2012/180363  0.48
2012 Lupold SE, Johnson T, Chowdhury WH, Rodriguez R. A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer. Plos One. 7: e36535. PMID 22590558 DOI: 10.1371/journal.pone.0036535  0.48
2012 Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT, Lupold SE. A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts. Nucleic Acids Research. 40: 6821-33. PMID 22505577 DOI: 10.1093/nar/gks308  0.48
2011 Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angewandte Chemie (International Ed. in English). 50: 9167-70. PMID 21861274 DOI: 10.1002/anie.201102872  0.48
2011 Ni X, Castanares M, Mukherjee A, Lupold SE. Nucleic acid aptamers: Clinical applications and promising new horizons Current Medicinal Chemistry. 18: 4206-4214. PMID 21838685 DOI: 10.2174/092986711797189600  0.48
2011 Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts. The Journal of Clinical Investigation. 121: 2383-90. PMID 21555850 DOI: 10.1172/JCI45109  0.48
2011 Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE, Rodriguez R. Does valproic acid induce neuroendocrine differentiation in prostate cancer? Journal of Biomedicine & Biotechnology. 2011: 607480. PMID 20981253 DOI: 10.1155/2011/607480  0.48
2010 Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE. Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening. Cancer Research. 70: 9549-53. PMID 20670952 DOI: 10.1158/0008-5472.CAN-10-1760  0.48
2010 Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R. Armoring CRAds with p21/Waf-1 shRNAs: The next generation of oncolytic adenoviruses Cancer Gene Therapy. 17: 585-597. PMID 20448671 DOI: 10.1038/cgt.2010.15  0.48
2010 Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R. Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer. International Journal of Radiation Biology. 86: 220-9. PMID 20201650 DOI: 10.3109/09553000903419338  0.48
2010 Ribas J, Lupold SE. The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer. Cell Cycle (Georgetown, Tex.). 9: 923-9. PMID 20160498  0.48
2009 Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research. 69: 7165-9. PMID 19738047 DOI: 10.1158/0008-5472.CAN-09-1448  0.48
2009 Byun Y, Mease RC, Lupold SE, Pomper MG. Recent Development of Diagnostic and Therapeutic Agents Targeting Glutamate Carboxypeptidase II (GCPII) Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications. 881-910. DOI: 10.1002/9780470508169.ch36  0.48
2008 Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG. Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry. 51: 7933-43. PMID 19053825 DOI: 10.1021/jm801055h  0.48
2008 Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA) Journal of Medicinal Chemistry. 51: 4504-4517. PMID 18637669 DOI: 10.1021/jm800111u  0.48
2007 Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R. A novel method for generating and screening peptides and libraries displayed on adenovirus fiber. Nucleic Acids Research. 35: e138. PMID 17965092 DOI: 10.1093/nar/gkm914  0.48
2007 Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1495-503. PMID 17565351 DOI: 10.1038/  0.48
2006 Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 768-78. PMID 16990052 DOI: 10.1016/j.ymthe.2006.07.009  0.48
2006 Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 319: 533-42. PMID 16868035 DOI: 10.1124/jpet.106.106658  0.48
2004 Lupold SE, Rodriguez R. Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. Molecular Cancer Therapeutics. 3: 597-603. PMID 15141017  0.48
2002 Lupold SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research. 62: 4029-33. PMID 12124337  0.48
1996 Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes & Development. 10: 1219-32. PMID 8675009  0.48
1996 Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proceedings of the National Academy of Sciences of the United States of America. 93: 2442-7. PMID 8637893 DOI: 10.1073/pnas.93.6.2442  0.48
1995 Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene. 10: 2103-11. PMID 7784055  0.48
Show low-probability matches.